Your browser doesn't support javascript.
loading
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.
Steens, Jean-Marc; Scherrer, Didier; Gineste, Paul; Barrett, P Noel; Khuanchai, Supparatpino; Winai, Ratanasuwan; Ruxrungtham, Kiat; Tazi, Jamal; Murphy, Robert; Ehrlich, Hartmut.
Afiliação
  • Steens JM; Abivax, Paris, France.
  • Scherrer D; Abivax, Paris, France.
  • Gineste P; Abivax, Paris, France Paul.Gineste@abivax.com.
  • Barrett PN; Independent Consultant, c/o Abivax, Paris, France.
  • Khuanchai S; Department of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Winai R; Department of Preventive and Social Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Ruxrungtham K; HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Chulalongkorn University Hospital, Bangkok, Thailand.
  • Tazi J; Institut de Genetique Moleculaire, University of Montpellier, Montpellier, France.
  • Murphy R; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Ehrlich H; Abivax, Paris, France.
Antimicrob Agents Chemother ; 61(7)2017 07.
Article em En | MEDLINE | ID: mdl-28507108
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinolinas / HIV-1 / Fármacos Anti-HIV Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinolinas / HIV-1 / Fármacos Anti-HIV Idioma: En Ano de publicação: 2017 Tipo de documento: Article